




PHARMACEUTICAL 2020

ChemoCentryx Inc.
Rank 219 of 358





PHARMACEUTICAL 2020

ChemoCentryx Inc.
Rank 219 of 358



The relative strengths and weaknesses of ChemoCentryx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ChemoCentryx Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 30% points. The greatest weakness of ChemoCentryx Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 33%, being 3.2% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	174,362
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	59,080
Liabilities, Non-Current	20,908
Other Assets	32,567
Other Compr. Net Income	516
Other Expenses	0
Other Liabilities	63,095
Other Net Income	2,814
Other Revenues	36,128
Property and Equipment	2,154
Research and Development	70,276
Selling, General and Administrative Expense	24,155

Output Variable	Value in 1000 USD
Assets	209,083
Liabilities	143,083
Expenses	94,431
Revenues	36,128
Stockholders Equity	66,000
Net Income	-55,489
Comprehensive Net Income	-55,231
Economic Capital Ratio	33%